Research programme: interleukin-4 antagonists - Fournier/Zambon
Alternative Names: IL-4 antagonists - Fournier/ZambonLatest Information Update: 14 Aug 2007
At a glance
- Originator Laboratoires Fournier; Zambon Group SpA
- Developer Zambon Group SpA
- Class
- Mechanism of Action Interleukin 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypersensitivity; Respiratory tract disorders
Most Recent Events
- 02 May 2002 Preclinical trials in Allergy in Switzerland (unspecified route)
- 02 May 2002 Preclinical trials in Respiratory tract disorders in Switzerland (unspecified route)